|Application ||IHC-P, E|
|Other Accession||NP_115805, 45331215|
|Calculated MW||72759 Da|
|Application Notes||LZTS2 antibody can be used for detection of LZTS2 by immunohistochemistry at 5 µg/mL.|
|Target/Specificity||LZTS2; LZTS2 antibody is predicted to not cross-react with other LZTS family members.|
|Reconstitution & Storage||LZTS2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||LZTS2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Negative regulator of katanin-mediated microtubule severing and release from the centrosome. Required for central spindle formation and the completion of cytokinesis. May negatively regulate axonal outgrowth by preventing the formation of microtubule bundles that are necessary for transport within the elongating axon. Negative regulator of the Wnt signaling pathway. Represses beta-catenin-mediated transcriptional activation by promoting the nuclear exclusion of beta-catenin.|
|Cellular Location||Cytoplasm. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Note=Localized to the centrosome throughout the cell cycle. Localized to the midbody in cells undergoing cytokinesis|
|Tissue Location||Highly expressed in prostate and testis, and at slightly lower levels in spleen, thymus, uterus, small intestine and colon.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
LZTS2 Antibody: The leucine zipper putative tumor suppressor 2 (LZTS2, also known as LAPSER1), a member of the LZTS family, is a negative regulator of the Wnt signaling pathway. It represses beta-catenin-mediated transcriptional activation by promoting the nuclear exclusion of beta-catenin. LZTS2 is involved in cytokinesis and regulates katanin-mediated microtubule severing and release from the centrosome. LZTS2 may negatively regulate axonal outgrowth by preventing the formation of microtubule bundles that are necessary for transport within the elongating axon. LZTS2 is highly expressed in testis and prostate, but it is deleted in multiple cancers, including prostate tumors, suggesting that LZTS2 acts as a potential tumor suppressor.
Thyssen G, Li TH, Lehmann L, et al. LZTS2 is a novel beta-catenin-interacting protein and regulates the nuclear export of beta-catenin. Mol. Cell. Biol. 2006; 26:8857-67
Sudo H and Maru Y. LAPSER1/LZTS2: a pluripotent tumor suppressor linked to the inhibition of katanin-mediated microtubule severing. Hum. Mol. Genet. 2008; 17:2524-40
Sudo H and Maru Y. LAPSER1 is a putative cytokinetic tumor suppressor that shows the same centrosome and midbody subcellular localization pattern as p80 Katanin. FASEB J. 2007; 21:2086-100.
Cabeza-Arvelaiz Y, Thompson TC, Sepulveda JL, et al. LAPSER1: a novel candidate tumor suppressor gene from 10q24.3. Oncogene 2001; 20:6707-17
If you have any additional inquiries please email technical services at email@example.com.